Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way.

Breast carcinoma comprises a group of diseases with specific clinical, histopathologic and molecular properties. Traditional classification use morphology to divide tumors into separate categories with differing behavior and prognosis. However, there are limitations of traditional classification systems, and new molecular methods are expected to improve classification systems. Molecular subtypes of breast carcinomas have been characterized in the last 11 years, and have been studied extensively. Much of the information accumulated in recent years, and molecular taxonomy seems to be still developing and undergoing change. The main question is whether new molecular techniques such as gene expression profiling will be accepted as gold standard in determining breast cancer subtypes, and whether molecular classification is useful in specific subtypes of breast cancer as it is in ductal carcinoma (nonspecific type). In addition, critical review of the literature reveals major problems such as poor definition, lack of reproducibility and lack of quality control in current molecular techniques and classifications. Therefore, current molecular approaches are not yet used in routine clinical practice and treatment guidance since they are immature and can even lead to incorrect assessment.

[1]  J. Lamovec,et al.  Metastatic pattern of infiltrating lobular carcinoma of the breast: An autopsy study , 1991, Journal of surgical oncology.

[2]  Umberto Veronesi,et al.  Rethinking TNM: breast cancer TNM classification for treatment decision-making and research. , 2006, Breast.

[3]  J. Reis-Filho,et al.  Breast cancer precursors revisited: molecular features and progression pathways , 2010, Histopathology.

[4]  C. Fan,et al.  PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer , 2012, Breast Cancer Research and Treatment.

[5]  Sunil R Lakhani,et al.  Pleomorphic lobular carcinoma of the breast: molecular pathology and clinical impact. , 2009, Future oncology.

[6]  I. Ellis,et al.  Lobular breast carcinoma and its variants. , 2010, Seminars in diagnostic pathology.

[7]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Melissa P. Murray,et al.  Is pleomorphic lobular carcinoma really a distinct clinical entity? , 2008, Journal of surgical oncology.

[9]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  I. Ellis,et al.  Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. , 2008, European journal of cancer.

[11]  R. Gelber,et al.  Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[13]  J. Reis-Filho,et al.  Histological and molecular types of breast cancer: is there a unifying taxonomy? , 2009, Nature Reviews Clinical Oncology.

[14]  Jorge S. Reis-Filho,et al.  Microarray-Based Class Discovery for Molecular Classification of Breast Cancer: Analysis of Interobserver Agreement , 2011, Journal of the National Cancer Institute.

[15]  B. Kreike,et al.  Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype‐matched ductal and lobular carcinomas , 2010, The Journal of pathology.

[16]  I. Ellis,et al.  High Frequency of Coexistence of Columnar Cell Lesions, Lobular Neoplasia, and Low Grade Ductal Carcinoma In Situ With Invasive Tubular Carcinoma and Invasive Lobular Carcinoma , 2007, The American journal of surgical pathology.

[17]  N. Weidner,et al.  Pleomorphic variant of invasive lobular carcinoma of the breast. , 1992, Human pathology.

[18]  L. Pusztai,et al.  Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy , 2006, Nature Clinical Practice Oncology.

[19]  J. Reis-Filho,et al.  Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet? , 2009, International journal of surgical pathology.

[20]  John Quackenbush,et al.  A three-gene model to robustly identify breast cancer molecular subtypes. , 2012, Journal of the National Cancer Institute.

[21]  Lajos Pusztai,et al.  Molecular classification of breast cancer: limitations and potential. , 2006, The oncologist.

[22]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  I. Ellis,et al.  Clinical and Biological Significance of E-cadherin Protein Expression in Invasive Lobular Carcinoma of the Breast , 2010, The American journal of surgical pathology.

[24]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[25]  V. Eusebi,et al.  Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation. , 1992, Human pathology.

[26]  P. Ravdin,et al.  Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Ashworth,et al.  Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas , 2008, The Journal of pathology.

[28]  Amy V Kapp,et al.  Discovery and validation of breast cancer subtypes , 2006, BMC Genomics.

[29]  G. Azabdaftari,et al.  Refinement of breast cancer classification by molecular characterization of histological special types , 2009 .

[30]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  R. Roylance,et al.  Multiple ways of silencing E‐cadherin gene expression in lobular carcinoma of the breast , 2001, International journal of cancer.

[32]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[33]  H Buerger,et al.  Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes , 1999, The Journal of pathology.

[34]  T. Mukohara Mechanisms of resistance to anti‐human epidermal growth factor receptor 2 agents in breast cancer , 2011, Cancer science.

[35]  N. Sneige,et al.  Clinical, Histopathologic, and Biologic Features of Pleomorphic Lobular (Ductal-Lobular) Carcinoma In Situ of the Breast: A Report of 24 Cases , 2002, Modern Pathology.

[36]  S. Lakhani,et al.  Molecular classification of breast cancer: is it time to pack up our microscopes? , 2011, Pathology.

[37]  A. Vincent-Salomon,et al.  Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma. , 2010, European journal of cancer.

[38]  Samuel Leung,et al.  Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.

[39]  R. Gelber,et al.  Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  H. Horlings,et al.  Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck , 2009, Proceedings of the National Academy of Sciences.

[41]  K. Camphausen,et al.  Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer , 2010, Breast Cancer Research and Treatment.

[42]  N. Sneige,et al.  Clinical, Histopathologic, and Biologic Features of Pleomorphic Lobular (Ductal-Lobular) Carcinoma In Situ of the Breast: A Report of 24 Cases , 2002 .

[43]  C. Singer,et al.  Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients , 2010, Clinical Cancer Research.

[44]  M. Borst,et al.  Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. , 1993, Surgery.

[45]  J. Baselga,et al.  A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers. , 2010, Cancer research.

[46]  P. Sorensen,et al.  Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. , 2002, Cancer cell.

[47]  Emad A. Rakha,et al.  Combinatorial biomarker expression in breast cancer , 2010, Breast Cancer Research and Treatment.

[48]  M. Campiglio,et al.  HER2 splice variants and their relevance in breast cancer , 2011 .

[49]  A. Luini,et al.  Lack of prognostic significance of “classic” lobular breast carcinoma: a matched, single institution series , 2009, Breast Cancer Research and Treatment.

[50]  S. Singletary,et al.  Breast Cancer Staging: Working With the Sixth Edition of the AJCC Cancer Staging Manual , 2006, CA: a cancer journal for clinicians.

[51]  B. Kreike,et al.  The molecular underpinning of lobular histological growth pattern: a genome‐wide transcriptomic analysis of invasive lobular carcinomas and grade‐ and molecular subtype‐matched invasive ductal carcinomas of no special type , 2010, The Journal of pathology.

[52]  S. Lakhani,et al.  Aberrant Expression of E-cadherin in Lobular Carcinomas of the Breast , 2008, The American journal of surgical pathology.

[53]  S. Schnitt Will Molecular Classification Replace Traditional Breast Pathology? , 2010, International journal of surgical pathology.

[54]  I. Ellis,et al.  The Nottingham prognostic index in primary breast cancer , 2005, Breast Cancer Research and Treatment.

[55]  Johan Staaf,et al.  Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  I. Ellis,et al.  Columnar Cell Lesions of the Breast: The Missing Link in Breast Cancer Progression?: A Morphological and Molecular Analysis , 2005, The American journal of surgical pathology.

[57]  A. Vincent-Salomon,et al.  Columnar Cell Lesions of the Breast , 2003, Advances in Anatomic Pathology.

[58]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[59]  Shu Ichihara,et al.  Breast cancer prognostic classification in the molecular era: the role of histological grade , 2010, Breast Cancer Research.